Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics is developing DCVax® personalized dendritic cell-based therapeutic vaccines for solid tumors. The Company’s lead program is DCVax®-L treatment for glioblastoma brain cancer, for which the Company has completed a Phase III prospective externally controlled trial showing significant extension of survival. The Company has also treated a variety of other solid tumors, with encouraging results, in compassionate use cases and other clinical trials.